CELU - celularity.com Debt to Book Capitalization Ratio

Graphic logo of Celularity (CELU)

Celularity Inc. (CELU) reduces medical risks by developing placenta-derived cell therapies for tissue regeneration and oncology. Financial dependency levels based on balance sheet capital on the GURU.Markets chart show a metric value of 0.00. While cryopreservation patents ensure product longevity, high innovation costs coupled with low biobanking revenues create a significant cash gap.

CELU (Celularity) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of celularity.com

This indicator measures the proportion of borrowed funds relative to the company's equity. The calculation is based on the ratio of total liabilities to the book value of assets minus debt. By analyzing the company's debt in proportion to its book capitalization, an investor assesses financial stability and leverage risks. For Celularity Inc. (CELU), such a balance is critical when scaling cellular products. This allows the company to finance costly developments in regenerative medicine without creating an excessive debt burden.

Who Celularity Inc. competes with

Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|BioCryst Corp - Debts to Net Assets|VERA: Debt to Book Capitalization Ratio|DNTH: Debt to Book Value|PHVS (Pharvaris) - Debt to Book Capitalization Ratio|Debt to Book Value AbCellera Bio|TRML (Tourmaline Corp) - Debt to Book Value|Debts to Book Capitalization PGEN|Debt to Book Capitalization Ratio Pharming Group N.V. PHAR|Debt to Book Value Ratio nektar.com (NKTR)|UPB: Debts to Book Capitalization|Debts to Book Value Zenas Bio ZBIO|IMNM: Debts to Book Capitalization|GOSS - Debt to Book Value|Debts to Book Capitalization KALV|SEPN (septerna.com) - Debts to Book Value|Debt to Book Capitalization Ratio Pieris Pharmaceuticals, Inc.|Debt to Book Capitalization Ratio Savara Inc (SVRA)|Debt to Book Value RIGL|Debts to Book Capitalization ANAB (AnaptysBio Inc.)|Debt to Book Capitalization Ratio Astria Therapeutics ATXS|Debt to Book Capitalization Ratio engene.com ENGN|RAPT Therapeutics, Inc. - Debts to Book Capitalization|JBIO: Debts to Book Capitalization|Debt to Book Capitalization Ratio Aclaris ACRS|Kyverna Therapeutics, Inc (KYTX) - Debt to Net Assets Ratio|TLSA: Debts to Book Capitalization|Debts to Net Assets cabalettabio.com (CABA)|Debt to Book Value Ventyx Biosciences, Inc.|Debt to Book Capital Theratechnologies, Inc. THTX|AVTX: Debt to Book Value|ELDN - Debts to Book Value|Debt to Book Value Agenus (AGEN)|CLYM - Debt to Net Assets Ratio|Zura Bio Limited - Debts to Book Capitalization|ATYR (aTyr Pharma Inc) - Debts to Net Assets|Debt to Book Capitalization Ratio Adagene Inc (ADAG)|Debt to Book Value Ratio Ikena Oncology, Inc.|Debts to Book Capitalization STTK (Shattuck Labs, Inc.)|Debt to Book Value equilliumbio.com EQ|Debt to Book Value CNTB|Debts to Net Assets Immunic Therapeutics IMUX|ATRA: Debts to Book Capitalization|IFRX - Debt to Book Value|Debts to Book Capitalization XFOR|ACET (Adicet Bio, Inc.) - Debts to Book Value|Debt to Book Capitalization Ratio INmune Bio|Debt to Book Capitalization Ratio Barinthus Biotherapeutics PLC (BRNS)|Debt to Book Value KZR|Debts to Book Capitalization SABS (SAB Biotherapeutics Inc)|Akari Therapeutics (AKTX) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio Enlivex Therapeutics Ltd ENLV|Debts to Book Capitalization Q32 Bio Corp (QTTB)|GOVX - Debt to Net Assets Ratio|EDSA: Debts to Book Capitalization|IBIO (iBio Corporation) - Debts to Book Capitalization|CARM - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio XTLB|Debt to Book Capitalization Ratio BOLT (Bolt Biotherapeutics)|Debt to Book Value hcwbiologics.com (HCWB)|Debts to Book Capitalization APVO (Aptevo Therapeutics Inc.)|AIM - Debts to Book Capitalization|Debt to Book Value Aditxt Corp (ADTX)|GRI - Debt to Net Assets Ratio|XORTX Therapeutics - Debts to Book Capitalization|HIND (Vyome Holdings Inc.) - Debts to Net Assets|Debt to Book Capitalization Ratio REVB|Debt to Book Value INDP|Debt to Book Capitalization Ratio SCNI (Scinai Immunotherapeutics)|Debt to Book Value calcimedica.com CALI|Debt to Book Value AFMD (Affimed N.V.)|Allakos Inc - Debts to Book Capitalization|HOOKIPA (HOOK) - Debt to Book Capitalization Ratio|IGMS - Debt to Book Value Ratio|Debts to Book Capitalization ITOS|oceanbiomedical.com (OCEA) - Debts to Book Value|Debts to Book Capitalization TCBP|Debt to Book Value Third Harmonic Bio Inc.